Syngene Q2 FY23 PAT up 11% to Rs. 102 Cr
Revenue from operations up 26% to Rs. 768 crores
Revenue from operations up 26% to Rs. 768 crores
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Transformation to pure-play Innovative Medicines company nears completion
The companies will leverage their respective proprietary technology platforms
Krsnaa Diagnostics plans to set up Tele-Pathology Reporting Centre in Pune
The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030
Subscribe To Our Newsletter & Stay Updated